体外药敏试验ATP-TCA与流式细胞仪在肝癌化疗中的应用

目的 探讨体外化疗药敏试验系统（ATP-TCA系统）联合流式细胞仪（FCM）在肝癌化疗中的应用及其结果之间的关系。方法 取24例肝癌切除，活检或穿刺组织行体外药敏试验和流式细胞仪P170检测，并分析二者间的关系。结果 ATP-TCA的可评估率为91.67%;10种化疗药物的敏感率分别为：氟尿嘧啶5.00%，诺消灵5.00%，顺铂14.26%，足叶乙甙19.05%，草酸铂19.05%,丝裂霉素23.81%，表阿霉素28.57%，开普拓45.46%，健择47.62%，泰素63.64%；P170检测阳性率为57.14%；丝裂霉素，表阿霉素的敏感率在P170阴性表达时高，开普拓健择，泰素的敏感率高且在P170阳性表达和阴性表达时无显著差异。结论 ATP-TCA法联合FCM可较好用于肝癌化疗药物的筛选；丝裂霉素，表阿霉素可用于P170阴性表达的病人，开普拓，健择，泰素可用于P170阳性表达的病人。

Application of in vitro ATP-TCA and FCM in chemotherapy of primary liver cancer

Objective To study the application of in vitro ATP tumor chemosensitivity assay (ATP-TCA) and flow cytometry (FCM) in chemotherapy of primary liver cancer. Methods The specimens of primary liver cancer from 24 patients were tested by ATP-TCA and FCM. Results Evaluable test results were achieved in 22 of the 24 patients and the evaluability was 91.6%. The sensitive rates of 5-Fluoruracil (5-Fu), mitoxantron (MIT), cisplatin (CDDP), etoposid (Vp-16), oxaliplatin (OXA), mitomycin C (MMC), epirubicin (EPI), irinotecan (CPT), gemcitabine (GEM) and paclitaxl (TAX) were 5.00%, 5.00%, 14.29%, 19.05%, 19.05%, 23.81%, 28.57%, 45.46%, 47.62% and 63.60%, respectively. The positive rate of P 170 was 57.14%. The sensitive rates of MMC and EPI were higher in P 170 negative patients than in P 170 positive ones. The sensitive rates of CPT, GEM and TAX were high and there was no difference in sensitivity between different P 170 expression patterns. Conclusions ATP-CTA and FCM can be applied in screening of chemotherapeutic agents for primary liver cancer. MMC and EPI can be used in patients with negative P 170 expression and CPT, GEM and TAX in those with positive P 170 expression.